Skip to main content
PMC home page
Molecular Pathology : MP logoLink to Molecular Pathology : MP
. 1999 Oct;52(5):263–268. doi: 10.1136/mp.52.5.263

p53 abnormalities in adenocarcinoma of the gastric cardia and antrum.

J F Fléjou 1, V Gratio 1, F Muzeau 1, R Hamelin 1
PMCID: PMC395708  PMID: 10748875

Abstract

AIM: To compare the frequency and type of p53 alterations (gene mutation and/or protein overexpression) in a consecutive series of surgically resected adenocarcinomas arising in the gastric cardia and gastric antrum, and to evaluate associations with clinicopathological findings (age, sex, and tumour histology, grade, and stage). METHODS: The series comprised 50 patients with adenocarcinoma of the cardia and 20 patients with adenocarcinoma of the antrum. p53 gene mutations (exons 5-8) were detected by denaturing gradient gel analysis and DNA sequencing. Nuclear p53 overexpression was detected by immunohistochemistry with the DO7 antibody. RESULTS: p53 gene mutations were found in 21 of 50 and five of 20 adenocarcinomas of the cardia and the antrum, respectively. Base transitions occurring at CpG dinucleotides were frequent in both types of tumour. p53 protein overexpression was seen in 32 of 50 and seven of 20 adenocarcinomas of the cardia and of the antrum, respectively. p53 gene mutation and/or protein overexpression were significantly more frequent in adenocarcinomas of the cardia (37 of 50) than in adenocarcinomas of the antrum (seven of 20). There were no differences in the clinicopathological characteristics of the tumours between p53 positive and p53 negative cases in both types of cancer. CONCLUSIONS: This study shows that p53 alterations are more frequent in adenocarcinoma of the cardia than in adenocarcinoma of the antrum. This feature is consistent with the clinical and epidemiological characteristics of these cancers, which suggest that adenocarcinoma arising in the gastric cardia might be related to oesophageal adenocarcinoma, and unrelated to adenocarcinomas of the gastric body and antrum.

Full Text

The Full Text of this article is available as a PDF (150.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antonioli D. A., Wang H. H. Morphology of Barrett's esophagus and Barrett's-associated dysplasia and adenocarcinoma. Gastroenterol Clin North Am. 1997 Sep;26(3):495–506. doi: 10.1016/s0889-8553(05)70309-5. [DOI] [PubMed] [Google Scholar]
  2. Baas I. O., Mulder J. W., Offerhaus G. J., Vogelstein B., Hamilton S. R. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol. 1994 Jan;172(1):5–12. doi: 10.1002/path.1711720104. [DOI] [PubMed] [Google Scholar]
  3. Cameron A. J., Lomboy C. T., Pera M., Carpenter H. A. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology. 1995 Nov;109(5):1541–1546. doi: 10.1016/0016-5085(95)90642-8. [DOI] [PubMed] [Google Scholar]
  4. Devesa S. S., Blot W. J., Fraumeni J. F., Jr Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998 Nov 15;83(10):2049–2053. [PubMed] [Google Scholar]
  5. Fléjou J. F., Muzeau F., Potet F., Lepelletier F., Fékété F., Hénin D. Overexpression of the p53 tumor suppressor gene product in esophageal and gastric carcinomas. Pathol Res Pract. 1994 Dec;190(12):1141–1148. doi: 10.1016/S0344-0338(11)80440-1. [DOI] [PubMed] [Google Scholar]
  6. Forman D., Webb P., Parsonnet J. H pylori and gastric cancer. Lancet. 1994 Jan 22;343(8891):243–244. [PubMed] [Google Scholar]
  7. Gabbert H. E., Müller W., Schneiders A., Meier S., Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer. 1995 Sep 1;76(5):720–726. doi: 10.1002/1097-0142(19950901)76:5<720::aid-cncr2820760503>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  8. Gleeson C. M., Sloan J. M., McGuigan J. A., Ritchie A. J., Russell S. E. Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. Cancer Res. 1995 Aug 1;55(15):3406–3411. [PubMed] [Google Scholar]
  9. Gleeson C. M., Sloan J. M., McGuigan J. A., Ritchie A. J., Weber J. L., Russell S. E. Ubiquitous somatic alterations at microsatellite alleles occur infrequently in Barrett's-associated esophageal adenocarcinoma. Cancer Res. 1996 Jan 15;56(2):259–263. [PubMed] [Google Scholar]
  10. Gleeson C. M., Sloan J. M., McGuigan J. A., Ritchie A. J., Weber J. L., Russell S. E. Widespread microsatellite instability occurs infrequently in adenocarcinoma of the gastric cardia. Oncogene. 1996 Apr 18;12(8):1653–1662. [PubMed] [Google Scholar]
  11. Gleeson C. M., Sloan J. M., McManus D. T., Maxwell P., Arthur K., McGuigan J. A., Ritchie A. J., Russell S. E. Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia. Br J Cancer. 1998;77(2):277–286. doi: 10.1038/bjc.1998.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gomyo Y., Ikeda M., Osaki M., Tatebe S., Tsujitani S., Ikeguchi M., Kaibara N., Ito H. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer. 1997 Jun 1;79(11):2067–2072. doi: 10.1002/(sici)1097-0142(19970601)79:11<2067::aid-cncr3>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  13. Goseki N., Takizawa T., Koike M. Differences in the mode of the extension of gastric cancer classified by histological type: new histological classification of gastric carcinoma. Gut. 1992 May;33(5):606–612. doi: 10.1136/gut.33.5.606. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994 Sep 15;54(18):4855–4878. [PubMed] [Google Scholar]
  15. Hamelin R., Fléjou J. F., Muzeau F., Potet F., Laurent-Puig P., Fékété F., Thomas G. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology. 1994 Oct;107(4):1012–1018. doi: 10.1016/0016-5085(94)90225-9. [DOI] [PubMed] [Google Scholar]
  16. Hamelin R., Jego N., Laurent-Puig P., Vidaud M., Thomas G. Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. Oncogene. 1993 Aug;8(8):2213–2220. [PubMed] [Google Scholar]
  17. Hurlimann J., Saraga E. P. Expression of p53 protein in gastric carcinomas. Association with histologic type and prognosis. Am J Surg Pathol. 1994 Dec;18(12):1247–1253. doi: 10.1097/00000478-199412000-00008. [DOI] [PubMed] [Google Scholar]
  18. Johnson H., Jr, Belluco C., Masood S., Abou-Azama A. M., Kahn L., Wise L. The value of flow cytometric analysis in patients with gastric cancer. Arch Surg. 1993 Mar;128(3):314–317. doi: 10.1001/archsurg.1993.01420150070013. [DOI] [PubMed] [Google Scholar]
  19. LAUREN P. THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand. 1965;64:31–49. doi: 10.1111/apm.1965.64.1.31. [DOI] [PubMed] [Google Scholar]
  20. Levine D. S. Barrett's oesophagus and p53. Lancet. 1994 Jul 23;344(8917):212–213. doi: 10.1016/s0140-6736(94)92993-9. [DOI] [PubMed] [Google Scholar]
  21. Liang Y. Y., Estève A., Martel-Planche G., Takahashi S., Lu S. H., Montesano R., Hollstein M. p53 mutations in esophageal tumors from high-incidence areas of China. Int J Cancer. 1995 May 29;61(5):611–614. doi: 10.1002/ijc.2910610505. [DOI] [PubMed] [Google Scholar]
  22. Maesawa C., Tamura G., Suzuki Y., Ogasawara S., Sakata K., Kashiwaba M., Satodate R. The sequential accumulation of genetic alterations characteristic of the colorectal adenoma-carcinoma sequence does not occur between gastric adenoma and adenocarcinoma. J Pathol. 1995 Jul;176(3):249–258. doi: 10.1002/path.1711760307. [DOI] [PubMed] [Google Scholar]
  23. Ming S. C. Gastric carcinoma. A pathobiological classification. Cancer. 1977 Jun;39(6):2475–2485. doi: 10.1002/1097-0142(197706)39:6<2475::aid-cncr2820390626>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  24. Montesano R., Hollstein M., Hainaut P. Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer. 1996 Jun 21;69(3):225–235. doi: 10.1002/(SICI)1097-0215(19960621)69:3<225::AID-IJC13>3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
  25. Morales T. G. Adenocarcinoma of the gastric cardia. Dig Dis. 1997 Nov-Dec;15(6):346–356. doi: 10.1159/000171610. [DOI] [PubMed] [Google Scholar]
  26. Muzeau F., Fléjou J. F., Belghiti J., Thomas G., Hamelin R. Infrequent microsatellite instability in oesophageal cancers. Br J Cancer. 1997;75(9):1336–1339. doi: 10.1038/bjc.1997.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Mönig S. P., Eidt S., Zirbes T. K., Stippel D., Baldus S. E., Pichlmaier H. p53 expression in gastric cancer: clinicopathological correlation and prognostic significance. Dig Dis Sci. 1997 Dec;42(12):2463–2467. doi: 10.1023/a:1018844008068. [DOI] [PubMed] [Google Scholar]
  28. Neshat K., Sanchez C. A., Galipeau P. C., Blount P. L., Levine D. S., Joslyn G., Reid B. J. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology. 1994 Jun;106(6):1589–1595. doi: 10.1016/0016-5085(94)90415-4. [DOI] [PubMed] [Google Scholar]
  29. Poremba C., Yandell D. W., Huang Q., Little J. B., Mellin W., Schmid K. W., Böcker W., Dockhorn-Dworniczak B. Frequency and spectrum of p53 mutations in gastric cancer--a molecular genetic and immunohistochemical study. Virchows Arch. 1995;426(5):447–455. doi: 10.1007/BF00193167. [DOI] [PubMed] [Google Scholar]
  30. Renault B., van den Broek M., Fodde R., Wijnen J., Pellegata N. S., Amadori D., Khan P. M., Ranzani G. N. Base transitions are the most frequent genetic changes at P53 in gastric cancer. Cancer Res. 1993 Jun 1;53(11):2614–2617. [PubMed] [Google Scholar]
  31. Seruca R., David L., Castedo S., Veiga I., Børresen A. L., Sobrinho-Simões M. p53 alterations in gastric carcinoma: a study of 56 primary tumors and 204 nodal metastases. Cancer Genet Cytogenet. 1994 Jul 1;75(1):45–50. doi: 10.1016/0165-4608(94)90214-3. [DOI] [PubMed] [Google Scholar]
  32. Shun C. T., Wu M. S., Lin J. T., Chen S. Y., Wang H. P., Lee W. J., Wang T. H., Chuang S. M. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer. Hepatogastroenterology. 1997 Mar-Apr;44(14):604–609. [PubMed] [Google Scholar]
  33. Soussi T., Legros Y., Lubin R., Ory K., Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer. 1994 Apr 1;57(1):1–9. doi: 10.1002/ijc.2910570102. [DOI] [PubMed] [Google Scholar]
  34. Souza R. F., Meltzer S. J. The molecular basis for carcinogenesis in metaplastic columnar-lined esophagus. Gastroenterol Clin North Am. 1997 Sep;26(3):583–597. doi: 10.1016/s0889-8553(05)70315-0. [DOI] [PubMed] [Google Scholar]
  35. Starzynska T., Bromley M., Ghosh A., Stern P. L. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer. 1992 Sep;66(3):558–562. doi: 10.1038/bjc.1992.314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Stemmermann G., Heffelfinger S. C., Noffsinger A., Hui Y. Z., Miller M. A., Fenoglio-Preiser C. M. The molecular biology of esophageal and gastric cancer and their precursors: oncogenes, tumor suppressor genes, and growth factors. Hum Pathol. 1994 Oct;25(10):968–981. doi: 10.1016/0046-8177(94)90056-6. [DOI] [PubMed] [Google Scholar]
  37. Tahara E., Semba S., Tahara H. Molecular biological observations in gastric cancer. Semin Oncol. 1996 Jun;23(3):307–315. [PubMed] [Google Scholar]
  38. Uchino S., Noguchi M., Ochiai A., Saito T., Kobayashi M., Hirohashi S. p53 mutation in gastric cancer: a genetic model for carcinogenesis is common to gastric and colorectal cancer. Int J Cancer. 1993 Jul 9;54(5):759–764. doi: 10.1002/ijc.2910540509. [DOI] [PubMed] [Google Scholar]
  39. Wang H. H., Antonioli D. A., Goldman H. Comparative features of esophageal and gastric adenocarcinomas: recent changes in type and frequency. Hum Pathol. 1986 May;17(5):482–487. doi: 10.1016/s0046-8177(86)80038-7. [DOI] [PubMed] [Google Scholar]
  40. Wu T. T., Watanabe T., Heitmiller R., Zahurak M., Forastiere A. A., Hamilton S. R. Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol. 1998 Jul;153(1):287–294. doi: 10.1016/S0002-9440(10)65570-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. dos Santos N. R., Seruca R., Constância M., Seixas M., Sobrinho-Simões M. Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. Gastroenterology. 1996 Jan;110(1):38–44. doi: 10.1053/gast.1996.v110.pm8536886. [DOI] [PubMed] [Google Scholar]
  42. van Dekken H., Geelen E., Dinjens W. N., Wijnhoven B. P., Tilanus H. W., Tanke H. J., Rosenberg C. Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas. Cancer Res. 1999 Feb 1;59(3):748–752. [PubMed] [Google Scholar]

Articles from Molecular Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES